1. Home
  2. NEXM vs CDXS Comparison

NEXM vs CDXS Comparison

Compare NEXM & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NEXM

NexMetals Mining Corp.

BUY

Current Price

$4.08

Market Cap

145.5M

Sector

N/A

ML Signal

BUY

Logo Codexis Inc.

CDXS

Codexis Inc.

HOLD

Current Price

$1.78

Market Cap

141.8M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEXM
CDXS
Founded
N/A
2002
Country
Canada
United States
Employees
N/A
N/A
Industry
Major Chemicals
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
145.5M
141.8M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
NEXM
CDXS
Price
$4.08
$1.78
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
73.7K
986.3K
Earning Date
02-20-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$52,932,000.00
Revenue This Year
N/A
$15.64
Revenue Next Year
N/A
$5.23
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.37
$1.52
52 Week High
$10.35
$5.43

Technical Indicators

Market Signals
Indicator
NEXM
CDXS
Relative Strength Index (RSI) 55.39 56.19
Support Level $3.76 $1.61
Resistance Level $4.22 $1.74
Average True Range (ATR) 0.25 0.07
MACD 0.02 0.02
Stochastic Oscillator 62.84 100.00

Price Performance

Historical Comparison
NEXM
CDXS

About NEXM NexMetals Mining Corp.

NexMetals Mining Corp is a mineral exploration and development company focused on discovering and advancing high-quality copper-nickel-cobalt-platinum element metals (Cu- Cu-Ni-Co-PGE) resources. The group prioritizes projects in stable, mining-friendly jurisdictions with supportive foreign investment and rule-of-law standards. Its projects are Botswana and Canada.

About CDXS Codexis Inc.

Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.

Share on Social Networks: